HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of Carevix™ from the U.S. Food and Drug Administration (FDA). ASPIVIX’s novel Cervical Stabilizer will allow millions of women across the USA access to significantly less painful treatments and IUD insertions.
ASPIVIX 510(k) Clearance by FDA news release_Draft_EN-V3
HEMEX is a global provider of clinical research services to small and medium-sized life sciences companies in diverse therapeutic areas. By combining extensive clinical expertise, commitment to speed, and dedication to patient-centric approaches, HEMEX supports its clients to complete their clinical trials faster. Advancing healthcare and improving patient outcomes, HEMEX’s priority is ensuring patients can have access to lifesaving therapies within a short clinical journey. Through its subsidiaries, Hemex Germany GmbH and Hemex Benelux AV, the company can also secure project funding through different EU funds. For more information, visit https://hemex.ch/